Cantor Fitzgerald Forecasts Sanara MedTech FY2025 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Sanara MedTech in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($1.09) for the year. Cantor Fitzgerald has a “Overweight” rating and a $44.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.33) per share.

Separately, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Sanara MedTech in a research report on Thursday.

Sanara MedTech Price Performance

Shares of SMTI opened at $37.72 on Thursday. The stock has a 50 day moving average of $34.66 and a 200-day moving average of $32.84. Sanara MedTech has a 52 week low of $26.00 and a 52 week high of $40.75. The firm has a market cap of $329.67 million, a price-to-earnings ratio of -38.10 and a beta of 1.55. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI) last issued its earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.28. The business had revenue of $21.67 million during the quarter. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. During the same quarter in the previous year, the firm posted ($0.13) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SMTI. JPMorgan Chase & Co. raised its holdings in Sanara MedTech by 127.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock worth $123,000 after buying an additional 2,272 shares during the period. Barclays PLC boosted its position in shares of Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after acquiring an additional 4,376 shares during the period. Fifth Third Bancorp bought a new position in Sanara MedTech in the 4th quarter valued at about $898,000. State Street Corp grew its holdings in shares of Sanara MedTech by 9.2% during the 3rd quarter. State Street Corp now owns 58,688 shares of the company’s stock valued at $1,775,000 after purchasing an additional 4,932 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Sanara MedTech by 4.4% in the third quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock valued at $2,670,000 after purchasing an additional 3,755 shares during the period. Institutional investors and hedge funds own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.